Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines to send his nomination to the full chamber.

There is also an FDA box warning for thyroid C-cell tumors ... but the drug does not have FDA approval for this use. Zepbound is an injectable weight-loss drug for people who have obesity or ...

Semaglutide's main competitor in the GLP-1 RA therapy market is Eli Lilly's (LLY) tirzepatide, which is marketed for diabetes as Mounjaro and for weight loss as Zepbound.

In a study of Eli Lilly’s Zepbound, weight loss increased (PDF) from 20.9% after 36 weeks to 25.8% after 88 weeks. The top-line data shared by Novo Friday lack important details, including ...

Lilly’s weekly Zepbound is the frontrunner among obesity treatments on the market — helping patients lose an average of 20.2% of their body weight over a 72-week period. However, by comparison, ...

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

Results published in December from a head-to-head trial run by Eli Lilly confirmed that Zepbound offered greater weight loss than Wegovy. Powell said if Novo Nordisk had run a more conventional ...

Her doctor prescribed the cheaper, generic version of the weight-loss drug after her insurer refused to cover Zepbound, the brand-name version ... As we talk, she marvels that she's had a box of ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in ... Mounjaro and Zepbound, have become household names and key tools in the fight against ...